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This study aimed to evaluate the in vitro performance of activated platelet-rich plasma associated with porous sponges of chitosan
as a composite scaffold for proliferation and osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells.
The sponges were prepared by controlled freezing (−20, −80, or −196∘C) and lyophilization of chitosan solutions (1, 2, or 3% w/v).
The platelet-rich plasma was obtained from controlled centrifugation of whole blood and activated with calcium and autologous
serum.The composite scaffoldswere prepared by embedding the spongeswith the activated platelet-rich plasma.The results showed
the performance of the scaffolds was superior to that of activated platelet-rich plasma alone, in terms of delaying the release of
growth factors and increased proliferation of the stem cells. The best preparation conditions of chitosan composite scaffolds that
coordinated the physicochemical and mechanical properties and cell proliferation were 3% (w/v) chitosan and a −20∘C freezing
temperature, while −196∘C favored osteogenic differentiation. Although the composite scaffolds are promising for regenerative
medicine, the structures require stabilization to prevent the collapse observed after five days.
1. Introduction
In tissue engineering, a scaffold is a three-dimensionalmatrix
for the stimulation of cell proliferation and the formation
of new tissue. To achieve this goal, scaffolds must meet
some specific requirements such as mimicking the native
extracellular matrix (ECM) of the target tissue; allowing cell
attachment, migration, proliferation, and differentiation to
and maintenance of the target phenotype; promoting vascu-
larization and nutrient delivery; and having a biodegradation
rate and mechanical properties that are adequate to support
the formation of the new tissue [1, 2].
According to Crane and Everts, tissue regeneration is
based on a proliferation triangle composed of the three
fundamental elements of cells, growth factors (GFs), and
scaffolds, which are in a close relationship through their
capabilities.Thus, scaffolds provide the conductivematrix for
supporting the genic capability of progenitor cells mediated
by the inductive capability of GFs [3]. Optimal conditions
for tissue regeneration must come from the interaction of the
properties of those elements.
The cell responses to the surface chemistry of scaffolds
depend on their hydrophobicity, protein adsorption, surface
charge, and roughness, softness, and stiffness. Additionally,
the porous architecture characterized by the pore size, poros-
ity, connectivity, and tortuosity plays important roles, as
described and discussed by Chang and Wang [4]. Therefore,
bringing together all these properties in solid scaffolds is an
enormous technological challenge.
The fibrin matrix is the natural scaffold formed from the
coagulation cascade in the healing process. Under injury,
thrombin cleaves the soluble plasma protein fibrinogen into
peptide fragments, yielding insoluble fibrin peptides that
aggregate and form fibrils. A fibrin network is then formed,
which entraps platelets and other blood components [5, 6].
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Calcium acts as a cofactor of thrombin, modulates the
elongation of fibers during polymerization by promoting lat-
eral branching, and functions in clot stability [7, 8]. Calcium
and thrombin also activate platelets, allowing the release of
GFs and cytokines. Therefore, the fibrin matrix provides an
optimized medium for cell proliferation and healing.
Based on these features, platelet-rich plasma (PRP) has
been widely used in regenerative medicine. PRP is an autol-
ogous product prepared from whole blood by separating
the red blood cells and concentrating the platelets and
other components of plasma. However, although viscoelastic,
the fibrin matrix alone lacks stability to be efficient when
regenerative medicine is the goal.
To mimic the natural healing process and improve the
stability of the fibrin matrix, we propose in this work the
use of the fibrin network from activated PRP with porous
chitosan as a composite scaffold for tissue regeneration.
Our hypothesis is that the chemical nature of the chi-
tosan surface supports the fibrin network by electrostatic
attachment, thus prolonging its stability, without changing
the paracrine affinity of mesenchymal cells to fibrin fibers. As
a consequence, the composite scaffoldmust improve cell pro-
liferation and tissue differentiation compared to PRP alone.
Related works showed the effects of chitosan on blood
coagulation through the strong adhesion of platelets to
the surface of chitosan particles, as well as chitosan (0.1–
1mg/mL) incorporated with PRP to enhance the release
of PDGF-AB and TGF-𝛽1 from platelets [9, 10]. Shen et
al. demonstrated that chitosan could be an appropriate
substitute for thrombin, as an agonist in PRP preparation
[11]. Chang et al. showed that growth factors could sustain
release until 12 h at approximately 1 ng/mL from chitosan/
CaSO
4
/PRP microspheres after activation with thrombin
[12]. Kutlu et al. showed that scaffolds prepared by the freeze-
drying of PRP added to chitosan gel (2% w/v) were more
effective than chitosan sponges soaked with PRP on con-
trolled GF release [13]. Oktay et al. applied PRP-embedded
chitosan sponges to defects and showed a histological ten-
dency toward increased bone formation [14]. Mathews et
al. demonstrated that chitosan enhanced mineralization by
upregulating the genes associated with mineralization and
calcium-binding proteins [15].
Chitosan is a polysaccharide derived from chitin (copoly-
mers 𝛽-(1→ 4)-2-amino-2-deoxy-D-glucose and 𝛽-(1→ 4)-
2-acetamido 2-deoxy-D-glucose) found in the shells of
marine crustaceans and insects and the cell walls of some
fungi [16, 17].
In the last ten years, considerable attention has been given
to chitosan-based materials in the field of tissue engineering
[18, 19]. The beneficial properties of chitosan have been
proven, such as biodegradability [20, 21], biocompatibility
[22, 23], antibacterial activity [24, 25], cell adhesion [26, 27],
and wound healing properties [28, 29]. Moreover, the chem-
ical nature of chitosan gives many possibilities for ionic and
covalent modifications that allow for the modulation of the
mechanical and biological properties of biomaterials [30, 31].
Regarding the technological aspects, chitosan can be
easily processed in diverse forms in the absence of toxic
solvents, such as films [32], sponges [33, 34], fibers [35],
beads [36], hydrogels [37], and microparticles/nanoparticles
[38]. Furthermore, chitosan supports sterilization [39], is
abundant in nature, and requires only low-cost processing
in nonaggressive ecological conditions before being used as
a raw material [17].
Freeze-drying is the most common and simplest method
to produce porous chitosan scaffolds. The freezing process
provides the nucleation of ice crystals from solution and
further growth along the lines of thermal gradients. Exclusion
of the chitosan acetate salt from the ice crystal phase and
subsequent ice removal by lyophilization generate a porous
material [40, 41].
Madihally and Matthew reported that the pore size of
chitosan scaffolds produced by lyophilization can be con-
trolled within the range of 1–250𝜇m [33]. A more uniform
and interconnected pore structure can be obtained when
lower freezing temperatures are used. Furthermore, the pore
orientation is related to the geometry of the moldings used
and can also be controlled by changing thermal gradients
during freezing [42].
Themicrostructure, crystallinity, andmechanical strength
of the porous chitosan matrix also can be controlled by the
chitosan concentration, molecular weight, and deacetylation
degree [33, 43].
In this work, the effects of PRP association were studied
regarding the porous structure of solid sponges, which were
produced by varying chitosan concentration and freezing
conditions. The biological performance of association was
evaluated in terms of growth factor release kinetics, prolifera-
tion, and osteogenic differentiation of seeded human adipose
tissue-derived mesenchymal stem cells (h-AdMSCs).
2. Experimental
2.1. Materials. Chitosan (average molecular weight [Mw] =
4 × 105Da, degree of deacetylation = 83±4%) was purchased
from Polymar (Fortaleza, CE, Brazil) and purified according
to the protocol described by Nasti et al. [44]. Other chemicals
were of reagent grade and were used without any further
purification. All biological experiments were performed with
human adipose tissue-derived stem mesenchymal cells (h-
AdMSCs) and approved by the Ethics Committee of the
Medical Sciences School of the University of Campinas
(UNICAMP; CAAE: 0972.0.146.000-11). The donors were
healthy individuals aged between 30 and 40 years old who
were previously assessed through clinical examinations.
2.2. Methods
2.2.1. Preparation of Porous Chitosan Scaffolds (PCHTs).
PCHTs were prepared by freezing at a controlled temperature
of a chitosan solution previously poured in 24-well culture
plates (TPP, polystyrene, diameter = 15.4mm) to give them
a cylindrical shape, followed by lyophilizing in lyophilizer
L101 (Liobras, Sa˜o Carlos, SP, Brazil) at a temperature of
approximately −30∘C for 48 hours.
Effects of Chitosan Concentration. Chitosan solutions with
concentrations of 1, 2, or 3% (w/v) were prepared by
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dissolution in 0.2mol L−1 acetic acid for 24 hours at room
temperature.The solutions were frozen at −20∘C for 24 hours
and lyophilized.
Effects of Freezing Conditions. Chitosan solution (3%w/v) was
prepared as previously described. The solution was frozen at
−20∘C in a freezer for 24 hours;−80∘C in an ultrafreezer for 24
hours; or −196∘C by immersion in liquid N
2
; and lyophilized.
2.2.2. Characterization of Porous Chitosan Scaffolds (PCHTs)
Morphology and Pore Size. The morphology of PCHTs was
evaluated by scanning electron microscopy (SEM) using an
LEO 440i Electron Microscopy/Oxford (Cambridge, Eng-
land) operated at 5 kV accelerating voltage.The scaffolds were
gold-coated using a sputter coater POLARON SC7620, VG
Microtech (Uckfield, England) for 180 s at a current of 3mA.
Pore size (𝑛 = 20) was measured using software Image J 1.47t.
Mechanical Properties. Mechanical compression tests of
PCHTs (𝑛 = 3) were performed using a Universal Testing
Machine,MTSmodel 810-Flex Test 40 (MTS Systems Corpo-
ration, Eden Prairie, MN, USA) up to 60% strain, according
to Correia et al. [45]. The testing machine was equipped with
a 1.5 kN load cell, and the loading rate was 5mm/min. Young’s
modulus was calculated in the initial linear section of the
stress-strain curve, when the strain was lower than 10%.
Degradation in PBS. The degradation profile of the PCHTs
in PBS at 37∘C was performed by the gravimetric method
described by Tang and Spector through measurements of
remaining weight [46].
Water Sorption. The water sorption was determined by
swelling of PCHTs (previously weighted) in PBS (LB Labor-
clin, Pinhais, PR, Brazil) at pH 7.4 for 24 hours at 37∘C. The
swollen PCHTs were weighed after the removal of excess
water by keeping the surfaces on a filter paper. The swelling
ratio (SR) was also calculated using
SR = 𝑤𝑠
𝑤𝑑
, (1)
where 𝑤𝑠 and 𝑤𝑑 are the weights of the scaffolds in the
swelled state and the dry state, respectively.
Porosity. The porosity (𝜀) of the PCHTs was determined
according to the protocol used by Wang et al. and calculated
by [47]
𝜀 (%) =
𝑉𝑚 − (𝑤𝑚/𝜌)
𝑉𝑚
× 100,
(2)
where𝑉𝑚 is the total volume of PCHTs (cm3), 𝜌 is the density
of nonporous CHT (1.342 g/cm3), and 𝑤𝑚 is the weight of
sponge (g). Values are expressed as the means ± standard
deviation (𝑛 = 3).
Cell Compatibility. The compatibility was carried out by
exposing PCHTs to h-AdMSCs followed by cultivation
at 37∘C for 24 hours and evaluation by MTT assay
(3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) (MTT, Molecular Probes) according to a modified
Mosmann method [48]. TheMTT assay is a colorimetric test
based on the reduction of yellow tetrazolium salt into a purple
formazan product in presence of cells [49].
2.2.3. PRP Preparations
PRP Concentration. P-PRP (plasma rich in platelets and
poor in leukocytes) was prepared according to Perez et al.
[50]. Briefly, whole blood (WB) was collected into 3.5mL
vacuum tubes (Vacuette, Campinas, SP, Brazil) containing
sodium citrate 3.2% (w/v) as an anticoagulant. WB was
initially centrifuged in a Rotina 380R centrifuge (Hettich
Zentrifugen, Tuttlingen, Germany) at 100×g for 10 minutes
at 25∘C. After the formation of three layers (a bottom layer
composed mainly of red blood cells (RBCs); an upper layer
composed of plasma, platelets, and some WB cells; and
an intermediate layer, or buffy coat, composed mostly of
WB cells), only the upper layer was collected to obtain P-
PRP. The concentration of platelets, WB cells, and RBCs
in WB and P-PRP were determined using the ABX Micros
ES 60 hematology analyzer (HORIBA ABX Diagnostics,
Montpellier, France).
P-PRPActivation. Activated P-PRP (𝑎P-PRP)was obtained by
adding autologous serum (Ser) and 10% (w/v) CaCl
2
solution
as agonists using the following proportions: agonist/P-PRP =
20% (v/v), Ser/CaCl
2
volumetric ratio = 9. Autologous serum
was prepared by collecting 5mL of WB in tubes without
anticoagulant. After 30 minutes to form clots, WB was
centrifuged at 2000×g for 10 minutes [51].
2.2.4. The Composite Scaffolds (𝑎P-PRP/PCHTs)
Preparation. 𝑎P-PRP/PCHTs was prepared for embedding by
dripping 𝑎P-PRP, immediately after activation, onto PCHTs.
The preparation was carried out in 48-well microplates using
a ratio of 200𝜇L of 𝑎P-PRP to 10–20mg of PCHTs.
Release of GFs. The release of platelet-derived growth factor
AB (PDGF-AB) and transforming growth factor 𝛽1 (TGF-
𝛽1) was performed after 1 hour of gelation of 𝑎P-PRP
associated with PCHTs in the presence of the culturemedium
(Dulbecco’s Modified Eagle’s Medium (DMEM-LG) (Gibco,
Grand Island,NY,USA)with low glucose concentration).The
culturemedium (1.5mL) was added to 𝑎P-PRP/PCHTs in 48-
wellmicroplates, whichweremaintained in an incubatorwith
5% CO
2
throughout the assays. The total volume of culture
medium was withdrawn at 3, 6, 12, 24, and 72 hours, and the
same volume of fresh medium was replaced without remov-
ing the hydrogels from the wells. The samples were stored
at −80∘C for further characterization. The concentrations
of the released GFs PDGF-AB and TGF-𝛽1 were measured
using enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions and specifications.
h-AdMSCs Proliferation. The cultivation of h-AdMSCs was
carried out in 24-well tissue culture plates by adding 1mL
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DMEM to the seeded composite scaffolds (𝑛 = 4). The
composite scaffolds seeded were maintained at 37∘C for 10
days. Cell proliferation was quantified using the thiazolyl
blue tetrazolium bromide (MTT) assay. At 3, 5, 7, and 10
cultivation days, the composite scaffolds were removed and
transferred to 24-well plates. MTT (1mL of 1mg/mL) was
then added, and the cultivation proceeded at 37∘C for 4
hours. The MTT solution was then discarded, and 1mL of
DMSO was added to dissolve the purple formazan crystals.
The samples were shaken at 120 rpm for 30min to ensure
homogeneous dissolution of the formazan dye, and then
200𝜇L of each sample was transferred to a 96-well plate.
Optical density was measured at 595 nm using a microplate
reader (FilterMax F5, Molecular Devices).
The isolation and precultivation of h-AdMSCs as well as
the cell seeding were performed as described below.
h-AdMSCs Isolation and Precultivation. Human subcuta-
neous adipose tissue that was initially acquired from lipo-
suction surgery was washed with sterile PBS, separated
into fractions of 10 g, digested with 20mg of collagenase
type 1A and maintained in 20mL of DMEM-LG containing
10% BSA (bovine serum albumin) and 10 𝜇L of gentamicin
for 30min in a 37∘C bath. After complete digestion, the
reaction was quenched with 10mL fetal bovine serum (FBS)
and immediately centrifuged for 15min at 1500 rpm. The
supernatant was discarded, and the pellet was suspended in
10mLDMEM-LGwith 10%FBS.After precultivation for 24 h,
the culturemediumwas changed every 3 days; after the fourth
passage, the cells were characterized by immunophenotyping
(data not shown) using flow cytometry and according to their
adipogenic, osteogenic, and chondrogenic differentiation and
then used in the subsequent experiments.
h-AdMSCs-Seeding. The precultured h-AdMSCs were trypsi-
nized and resuspended in P-PRP to a final cell concentration
of 1 × 104 cells/mL. P-PRP containing h-AdMSCs was acti-
vated and immediately embedded to the PCHTs in a 24-well
tissue culture plate, using 200 𝜇L of h-AdMSCs + 𝑎P-PRP per
10–20mg of PCHTs.The composite scaffolds with h-AdMSCs
were kept at room temperature for 45 minutes for consolida-
tion of the fibrin network. Pure PRP was used as control.
2.2.5. Images of the h-AdMSCs-Seeded Composite Scaffolds.
The images of the cell-seeded composite scaffolds were
obtained by scanning electron microscopy after 5 days of
h-AdMSCs proliferation. The cell-seeded composite scaffolds
were fixed in a solution of 4% paraformaldehyde and 2.5%
glutaraldehyde in phosphate buffer, pH 7.4, for 2 hours. The
samples were than dehydrated in ethanol for 15min intervals
in aqueous 50%, 70%, 95%, and 100% ethanol solutions
(2x) and dried at the critical point dryer BAL-TEC CPD
030 (Schalksmu¨hle, Germany). After gold coating (Sputter
Coater POLARON, SC7620, VG Microtech), the cell-seeded
composite scaffolds were visualized with a SEM (Leo440i,
LEO) with an accelerating voltage of 20 kV.
2.2.6. Induction of Osteogenic Differentiation. h-AdMSCs-
seeded in the composite scaffolds were induced to
differentiate into the osteogenic lineage by providing the
osteogenic medium containing DMEM-LG supplemented
with 10% FBS, 1% 𝛽-glycerol-phosphate (Sigma-Aldrich, St.
Louis, MO, USA), 1% L-ascorbic acid (Sigma-Aldrich, St.
Louis, MO, USA), 1% dexamethasone (Sigma-Aldrich, St.
Louis, MO, USA), and 1% penicillin/streptomycin solution
(Gibco, Grand Island, NY, USA). The medium was changed
every 7 days.
Evaluation of Differentiation. Differentiationwas evaluated by
measuring the alkaline phosphatase activity (ALP) on day
14. The supernatant (200𝜇L) was collected and mixed with
the same volume of p-nitrophenyl phosphate (SIGMAFAST
p-nitrophenyl phosphate tablets, Sigma, Saint Louis, MO,
USA) as substrate and incubated at room temperature for 30
minutes. Absorbance was read immediately at 405 nm.
2.2.7. Statistical Analysis. Each experiment was carried out in
triplicate unless otherwise specified. All results are presented
as themean± standard deviation (SD).The experimental data
from all the studies were analyzed using Analysis of Variance
(ANOVA). Statistical significance was set to 𝑃 value ≤ 0.05.
3. Results and Discussion
3.1. Experimental Design. In this study, we prepared novel
composite scaffolds by association of PRPwith the 3D-porous
structure of chitosan. First, different 3D-porous structures
of chitosan (PCHTs) were prepared by freeze-drying by
varying the CHT concentration and freezing conditions
(temperature and freezing rate). Second, the microstructure
and mechanical properties of the PCHTs were characterized
and evaluated for cell compatibility. The surface chemistry,
hydrophilicity, and positive charge of –NH
2
groups in acidic
medium were maintained unaltered.
The composite scaffolds (𝑎P-PRP/PCHTs) were obtained
by embedding the PCHTs with immediately activated P-PRP
in a 24-well microplate. The release of the GFs (PDGF-AB
and TGF-𝛽1) from the composite scaffolds was evaluated in
DMEMculturemedium.Afterwards, precultured h-AdMSCs
were added to PRP before activation in order to obtain
cell-seeded composite scaffolds. In vitro examination of h-
AdMSCs proliferation kinetics was performed over 10 days
by using the cell-seeded composite scaffolds in DMEM.
Additionally, osteogenic differentiationwas evaluated byALP
activity measurements after 14 days.
Thus, we verified the correlation between the structure
and function of PCHTs by controlling the concentration and
freezing conditions of chitosan solution.
3.2. Effects of Freezing Conditions and Chitosan
Concentration on PCHTs
3.2.1. Images of Porous Structure. Figures 1(a)–1(c) show
images of the porous structure from controlled freezing at
−20∘C by varying the concentration of the chitosan solution
(1, 2, or 3%) and subsequent lyophilization. The images
show highly porous structures with rounded pores that
are uniformly distributed, radially oriented, and visually
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Figure 1: SEM micrographs of PCHTs. Cross-sectional morphologies of (a) PCHTs 1% (−20∘C); (b) PCHTs 2% (−20∘C); (c) PCHTs 3%
(−20∘C); (d) PCHTs 3% (−80∘C); and (e) PCHTs 3% (−196∘C). Original magnification is ×100 and the scale bar represents 200 𝜇m.
interconnected, regardless of CHT concentration. Differ-
ences in chitosan molecular weight, deacetylation degree,
and purity make difficult comparisons even for similar
treatment. Madihally and Matthew, showed a higher pore
interconnectivity degree and more open pores for 1% (w/w)
chitosan concentration for a similar deacetylation degree, but
other properties were not characterized [33].
Freezing conditions produced amore prominent effect on
themorphology of the pores (Figures 1(d)-1(e)) attributed the
variations in the freezing rate used to achieve the tempera-
tures evaluated. In contrast with rounded pores at −20∘C (3%
CHT) (Figure 1(c)), we observed pores with leaf structure at
−80∘C (Figure 1(d)), while smaller and elongated open pores
were produced at −196∘C (Figure 1(e)). In all cases, the pores
were uniformly distributed and radially oriented and had a
high degree of interconnectivity.
The pore structures allow uniform cell spatial distribution
throughout the scaffold, facilitating homogeneous tissue
formation. Moreover, the differences in pore morphologies
obtained are suitable to several cell linage and type of tissue
to be regenerated.
3.2.2. Characterization of PCHTs
Physicochemical and Mechanical Properties. Table 1 shows
physicochemical characterization of the PCHTs. At −20∘C,
the mean diameter of rounded pores could be controlled
around the 300–400 𝜇m, regardless of the CHT concentra-
tion, although there is a large distribution.
However, the elongated pores from Figures 1(d)-1(e) were
markedly decreased with freezing conditions from 2615𝜇m
(−80∘C) to 280𝜇m (−196∘C) because crystal growth and
hence pore size are functions of both heat and mass transfer
rates, determined by the temperature and freezing rate. At
−80∘C, the observed differences in pore shape and size sug-
gest parallel ice crystal growth, which in turn was caused by
the strongly one-dimensional nature of the thermal gradients
established during freezing, as discussed by Madihally and
Matthew [33].
The diverse nature of tissue architectures requires scaf-
folds with optimal pore sizes, such as 5 𝜇m for neovascu-
larization [52], 5–15𝜇m for fibroblast ingrowth [53], 20𝜇m
for the ingrowth of hepatocytes [54], 200–900𝜇m for osteo-
conduction [55], and 20–125𝜇m for regeneration of adult
mammalian skin [56].
According to these data, the rounded pores obtained
at −20∘C or elongated at −196∘C are adequate for bone
tissue, although other properties could also influence the
choice. Moreover, because human adipose tissue-derived
mesenchymal stem cells (h-AdMSCs) exhibit a spindle-like
shape and are 80–100𝜇m in diameter and ∼200𝜇m in length
[57], the range of pore sizes in our PCHTs allows cells to
migrate freely into the scaffolds, favoring the formation of a
new tissue.
The porosity is also an important aspect of cell migration
and proliferation, guiding and promoting the formation of
new tissue. Porosity is defined as the percentage of void
space in a solid and is a morphological property independent
of material [58]. A porosity higher than 90% and pore
interconnectivity are basic requirements for scaffolds in tissue
engineering because they affect the diffusion of physiolog-
ical nutrients and gases to and the removal of metabolic
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Table 1: Physicochemical characterization of PCHTs.
CHT
concentration
(%)
Freezing temperature
(∘C)
Swelling
ratio
(𝑛 = 3)
Pore size
(𝜇m)
(𝑛 = 20)
Porosity
(%)
(𝑛 = 3)
Young’s moduli
(MPa)
(𝑛 = 3)
1 −20 6.5 ± 0.4 425 ± 102 97.1 ± 0.3 0.037 ± 0.002
2 −20 5.5 ± 0.9 418 ± 113 94.7 ± 0.8 0.5 ± 0.1
3 −20 4.7 ± 0.9 336 ± 138 93.1 ± 0.5 1.1 ± 0.1
3 −80 5.1 ± 0.9 2615 ± 600∗ 91.7 ± 0.3 0.28 ± 0.01
3 −196 6.4 ± 0.6 280 ± 62∗ 92.5 ± 0.1 1.01 ± 0.05
∗Mean longitudinal size.
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Figure 2: The weight loss of scaffolds with time in PBS at 37∘C as
a percentage of the original weight of the scaffold (𝑛 = 3). The data
are plotted with the means ± standard error. (◼) PCHTs 1% (−20∘C);
(e) PCHTs 2% (−20∘C); (󳵳) PCHTs 3% (−20∘C); (◻) PCHTs 3%
(−80∘C); and (O) PCHTs 3% (−196∘C).
waste and byproducts from cells that have penetrated the
scaffold [59, 60]. Moreover, the porosity often compromises
the mechanical and structural stability of the scaffolds and
must be evaluated in accordance with the application and
degradation rate of materials utilized [61].
The porosity values of PCHTs scaffolds ranged from 91.0
to 97.0%, which are adequate for TE, independent of CHT
concentration or freezing conditions. However, the porosity
decreased with increasing chitosan concentration. The high-
est porosity was provided from 1% chitosan solution, but
there was not a direct relationship with freezing conditions.
The PCHTs prepared at −80∘C showed a significantly lower
porosity even with higher pore size, probably due to their leaf
structure (Table 1).
To guide tissue regeneration, scaffolds should also have
sufficient mechanical strength during in vitro culturing to
maintain the spaces required for cell in-growth and matrix
elaboration [59]. Moreover, their mechanical properties
should be similar to the properties of tissues generated to
provide an adequate structural support in the stage of healing
[62].
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Figure 3: Proliferation of h-AdMSCs exposed to the PCHTs
scaffolds after 24 hours of cultivation. Negative control (NTC) =
DMEMwith 10% FBS; positive control (PTC) =DMEMwith phenol
0.5%. Mean ± standard deviation 𝑛 = 3. The population means are
significantly different from positive control at ∗
𝑃
< 0.05.
Scaffolds for the regeneration of hard tissue must exhibit
a mechanical modulus in the range of 10–1,500MPa, while
scaffolds for soft tissues must exhibit a mechanical modulus
in the range of 0.4–350MPa [63].
In this work, we observed a drastic decrease in Young’s
modulus (Table 1) with a decrease in CHT concentration.
Better mechanical properties were found for a CHT concen-
tration of 3%.
The PCHTs 3% (w/v) prepared at −80∘C showed lower
mechanical strength than those prepared at −20∘C and
−196∘C with the same CHT concentration, which could be
attributed to its leaf structure and pore size. There was no
significant difference (𝑃 < 0.05) in mechanical properties for
PCHTs 3% (w/v) frozen at −20∘C or −196∘C. Thus, the range
of Young’smoduli found for PCHTs suggests their application
for soft tissue engineering. For hard tissues, these scaffolds
must be crosslinked and/or reinforced by the addition of
fillers.
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Figure 4: Scanning electron microscopic images of 𝑎P-PRP/PCHTs after 5 days of cultivation of h-AdMSCs. (a) 𝑎-PRP; (b) 𝑎P-PRP/PCHTs
1% (−20∘C); (c) 𝑎P-PRP/PCHTs 2% (−20∘C); (d) 𝑎P-PRP/PCHTs 3% (−20∘C); (e) 𝑎P-PRP/PCHTs 3% (−80∘C); and (f) 𝑎P-PRP/PCHTs 3%
(−196∘C).
The water absorption capacity (swelling property) of the
scaffolds affects cell growth indirectly [64]. The hydration of
the scaffolds is a necessary step for cell incorporation and
proliferation.
PCHTs scaffolds showed a high swelling capacity in PBS
(pH 7.2) regardless of chitosan concentration and freez-
ing conditions, allowing for rapid hydration when culture
medium was added.
Degradation in PBS. Scaffold degradation is also an important
parameter for the formation of new tissue. The scaffold
degradation ratemust be tuned appropriately with the growth
rate of the new tissue in such a way that by the time the injury
site is completely regenerated, the scaffold is completely
degraded [55]. Degradation can occur through mechanisms
that involve physical or chemical processes and/or biological
processes that are mediated by biological agents, such as
enzymes [1].
Here, we evaluated in vitro the profile degradation of
PCHTs in PBS (pH 7.2) at 37∘C;we supposed that degradation
occurred by solubilization due to the presence of residual
acetate molecules.
Figure 2 shows the degradation profile of PCHTs.
We observed the highest weight loss, approximately 45%,
for PCHT 1% (−20∘C) after 7 days, while for PCHTs 2%
(−20∘C), 3% (−20∘C), and 3% (−196∘C) weight loss was
approximately 35% after 3 days. The PCHTs 3% (−80∘C)
showed the lowest weight loss, probably due to their leaf
structure retaining lower concentration of acetate molecules.
Our results suggest that the PCHTs need further stabiliza-
tion, to ensure the balance between tissue regeneration and
degradation rate of the scaffold.
3.2.3. Cell Compatibility. Figure 3 shows the cell compati-
bility of h-AdMSCs cultured in the presence of PCHTs, as
assayed by MTT. The results revealed no potential cytotox-
icity in 24 hours for the scaffolds according to the standard
values (PTC).
However, we observed lower proliferation of h-AdMSCs
on PCHTs prepared with chitosan concentration of 3% (w/v)
compared to the negative control.
Nevertheless, the PCHTs are potentially useful for in vivo
applications regardless of CHT concentration and freezing
conditions.
3.3. Characterization of the Composite Scaffolds
3.3.1. Images of the Cell-Seeded 𝑎P-PRP/PCHTs. SEM char-
acterization (Figure 4) of the 𝑎P-PRP/PCHTs on the 5th
day of culture showed fibrin networks covering the pores
and surface of PCHTs, as a consequence of the interaction
of fibrin fibers and CHT. This interaction supported cell
proliferation by improving the mechanical strength of the
fibrin network, in addition to providing additional surface
area to cell adhesion, proliferation, and differentiation.
3.3.2. Growth Factor Release. Figure 5 shows PDGF-AB and
TGF-𝛽1 release kinetics from 𝑎P-PCHTs determined by
ELISA.
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Figure 5: Release profiles of growth factors from 𝑎P-PRP in porous chitosan scaffolds as a function of ((a), (b)) chitosan concentrations and
((c), (d)) freezing conditions. (◼) PCHTs 1% (−20∘C); (e) PCHTs 2% (−20∘C); (󳵳) PCHTs 3% (−20∘C); (◻) PCHTs 3% (−80∘C), (O) PCHTs
3% (−196∘C), and (󳵻) P-PRP activated with Ca+2/thrombin (used as control); TGF-𝛽1 ((a), (c)); and PDGF-AB ((b), (d)). The concentration
of platelets in P-PRP was 472,250 pq/mm3. Activated P-PRP alone was used as control.
The curves show diffusion profiles, indicating no collapse
of the porous structure of chitosan scaffolds during the
course of the assays, regardless of the CHT concentration and
freezing conditions.
PDGF-AB released from PCHTs ended within 24 hours
of incubation, whereas TGF-𝛽1 tended to continue after 72
hours.
A controlled release of TGF-𝛽1 and PDGF-AB was
achieved for all CHT concentrations, related to the scaffolds
of activated P-PRP only.The slowest release was observed for
a chitosan concentration of 3%.
In contrast, for the PCHTs 3% freezing at −80∘C and
−196∘C, we observed a controlled release of TGF-𝛽1, but a
strong burst release of PDGF-AB.
Thus, PCHTs prepared with 3% CHT at −20∘C provided
a controlled release of PDGF-AB and TGF-𝛽1 and can be an
efficient vehicle for release of GFs from PRP.
3.3.3. h-AdMSCs-Seeded Proliferation. Figure 6 shows the
proliferation profile of h-AdMSCs cultured in 𝑎P-PRP/
PCHTs.
The cell number per well determined after 3 days
exceeded the number of seeded cells (1.4 × 104 cells/well)
in all the 𝑎P-PRP/PCHTs, meaning that the cells kept in
the matrices retained their viability, regardless of the CHT
concentration and freezing conditions.
The cell number per well of 𝑎P-PRP/PCHTs prepared
with 1, 2, and 3% (w/v) of chitosan (Figure 6(a)) showed
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Figure 6: Proliferation kinetic profiles of h-AdMSCs seeded in 𝑎P-PRP/PCHTs. (a) CHT concentration and (b) freezing conditions. (◼)
PCHTs 1% (−20∘C); (e) PCHTs 2% (−20∘C); (󳵳) PCHTs 3% (−20∘C); (◻) PCHTs 3% (−80∘C), (O) PCHTs 3% (−196∘C), and (󳵻) P-PRP
activated with Ca+2/thrombin (control). The concentration of platelets in P-PRP was 374,000 pq/mm3. Activated P-PRP alone was used as
control.
significant differences (𝑃 < 0.05) compared to control
(𝑎P-PRP). Therefore, PCHTs should have stabilized fibrin
networks as we initially hypothesized.
However, regarding freezing condition, no significant
variations for 𝑎P-PRP/PCHTs prepared at −80∘C or −196∘C
and 𝑎P-PRP were observed (Figure 6(b)). In all cases, cell
viability decreased after 7 days, probably due to collapse of
the structure.
We also observed that the exponential phase of the
cultures (Figure 6(a)) started after the maximum release of
GFs (Figure 5), and the decline phase matched the largest
weight loss of the PCHTs (Figure 2).
3.3.4. Induction of Osteogenic Differentiation. Osteogenic dif-
ferentiation of h-AdMSCs was investigated 14 days after cell
seeding. ALP, an early marker of osteogenic differentiation,
was determined, and the results are shown in Figure 7. The
expression of ALP activity showed no significant difference
(𝑃 < 0.05) with CHT concentration. However, higher
osteogenic differentiation was obtained with 𝑎P-PRP/PCHTs
3% (−196∘C).
4. Conclusions
Composite scaffolds were prepared with porous chitosan
and 𝑎-PRP. The performance of the composite scaffolds
was superior to 𝑎P-PRP alone, indicating that the porous
chitosan stabilized the fibrin network, supporting our initial
hypothesis.
Chitosan concentration and freezing conditions influ-
enced the physicochemical and biological properties of the
scaffolds. On the average, physicochemical, mechanical, and
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Figure 7: ALP activities of cells cultured on 𝑎P-PRP/PCHTs
scaffolds prepared with different CHT concentrations and freezing
conditions (statistically significant differences from blank, 𝑛 =
3, ∗
𝑃
< 0.05). Blank = the reagents used in the assay only.
The concentration of platelets in whole blood donors (average
of 2 donors) was 163,500 pq/mm3. After preparation of the PRP,
the platelets were concentrated approximately 1.74 times, with an
average final concentration of 303,000 pq/mm3.
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h-AdMSCs proliferation improved by the use of 3% (w/v)
chitosan and −20∘C freezing temperature, while −196∘C
favored osteogenic differentiation. Additional stabilization of
the porous structure is needed for applications in regenerative
medicine.
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